IP Verse

Biogaran competitive analysis

Loading summary...

Explore patent oppositions filed by Biogaran against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 30, 2025

Patent Number	Title	Applicant	Opposition Date
Get instant updates on new opposition filings by the company
EP3345604	Nalmefene For Reduction Of Alcohol Consumption In Specific Target Populations	H LUNDBECK	Mar 6, 2024
EP3578175	Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound	AMGEN	Aug 30, 2023
EP2653873	Compositions And Uses For Treating Multiple Sclerosis	BIOGEN IDEC MA	Apr 20, 2023
EP2959894	S1P Receptor Modulators For Treating Multiple Sclerosis	NOVARTIS	Jan 13, 2023
EP2478907	Methods And Compositions For Treating Cancer	COUGAR BIOTECHNOLOGY	Jan 14, 2022
EP2234617	Dosing Regimen Associated With Long Acting Injectable Paliperidone Esters	JANSSEN PHARMACEUTICA	Dec 23, 2021
EP3395338	Rapid Dissolution Formulation Of Cinacalcet Hcl	AMGEN	Jan 31, 2020
EP3260117	Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound	AMGEN	Jan 17, 2020
EP3395339	Rapid Dissolution Formulation Of A Cinacalcet Hcl	AMGEN	Jan 17, 2020
EP3395340	Rapid Dissolution Formulation Of Cinacalcet Hcl	AMGEN	Jan 17, 2020

Explore the latest publications and patents granted to Biogaran, showcasing their recent innovations and technological advancements.

Discover the latest PTAB cases involving Biogaran, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Biogaran with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 30, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
BIOGARAN	12	-	-	-
AMGEN	8	138	8	11
BIOGEN MA	-	52	-	7
NOVARTIS	6	422	-	21